Humanised anti-CD19 control CAR-T cell therapy - Kite Pharma

Drug Profile

Humanised anti-CD19 control CAR-T cell therapy - Kite Pharma

Alternative Names: Third generation humanised anti-CD19 control CAR-T cell therapy - Kite Pharma

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kite Pharma
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 17 May 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO - 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top